Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAR: Biologically-Adapted, Dose-Escalated Accelerated Radiotherapy for Ewing Sarcoma
NCT07188532Recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2025
- Primary completion
- Aug 2033
- Countries
- 1
01
Overview
Open-label trial in Ewing sarcoma and round cell sarcoma (4 cohorts), sponsored by Mayo Clinic. Primary endpoint: Reduction in local failure up to 2 years. Started Dec 2025; status: recruiting.
02
Conditions
Ewing sarcomaround cell sarcoma
Beyond the preview
Go deeper on NCT07188532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188532.